Cobas c 501

The age at diagnosis and time of evolution with T1DM was recorded. Kidney function was established by serum creatinine measurement (COBAS C-501 (Hitachi), microalbuminuria (MAU), and urinary creatinine (COBAS C-501). Estimated Glomerular filtration rate (eGFR) was calculated by Schwartz-modified equation (0.413 ∗ height/sCr) (41 (link)). The eGFR >140 ml/min/1.72 m² was considered hyperfiltration. The MAU >20 mg/L (42 (link)) and albumin/creatinine ratio (ACR) >30 mg/g (43 (link)) were considered positives for kidney dysfunction. The glycosylated hemoglobin A1c (HbA1c) (CDA-VANTAGE) was measured at the enrolling time. Besides, the median of three or four HbA1c levels measurement one year before the enrolling time was used to evaluate the metabolic control status.

TyG served as the chosen exposure variable, and we calculated the TyG index using the formula Ln [triglycerides (mg/dl) * fasting glucose (mg/dl)/2]. The concentrations of triglycerides and fasting glucose underwent determination through an enzymatic assay performed on an automatic biochemistry analyzer. Specifically, the Roche Modular P and Roche Cobas 6000 chemistry analyzers were employed to measure serum triglyceride concentration. Additionally, fasting plasma glucose levels were evaluated through the hexokinase-mediated reaction, utilizing the Roche/Hitachi Cobas C 501 chemistry analyzer.

The TyG index was calculated by TyG index = Ln [fasting TG (mg/dL) × fasting glucose (mg/dL)/2]. The measurement of triglycerides and fasting glucose were measured through enzymatic assays on Roche Modular P and Roche Cobas 6000 chemistry analyzers, respectively. The hexokinase-mediated reaction was utilized on Roche/Hitachi Cobas C 501 chemistry analyzers for measuring fasting glucose. The participants were classifed into four groups (Q1, Q2, Q3, Q4) by the quartiles of TyG index, and the Q1 group was used as the reference group.